Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LATE-BREAKING ABSTRACT FOR BB-301 PRESENTED AT THE MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL AND SCIENTIFIC CONFERENCE IN MARCH DEMONSTRATED DURABLE RESPONSES TO LOW DOSE BB-301 AT 12-MONTHS AND 24-MONTHS POST-TREATMENT AND FURTHER IMPROVEMENTS IN DEPTH OF RESPONSE FOLLOWING TREATMENT WITH HIGH DOSE BB-301 AT THE 3-MONTH POST-TREATMENT FOLLOW-UP TIME-POINT, WITH BOTH DOSES DEMONSTRATING DISEASE MODIFYING OUTCOMES BB-301 PHASE 1B/2A INTERIM CLINICAL STUDY RESULTS SELECTED FOR ORAL PRESENTATION AT THE 2026 AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) ANNUAL MEETING ON MAY 15 ADVANCEMENT OF COHORT 2 ENROLLMENT CONTINUES AS PATIENT 1 AND PATIENT 2 WERE BOTH SAFELY TREATED WITH HIGH DOSE BB-301 IN THE ONGOING PHASE 1B/2A CLINICAL STUDY OF BB-301; BENITEC REMAINS ON TRACK TO PROVIDE UPDATED INTERIM CLINICAL STUDY RESULTS IN 2H-2026 THE COMPANY REMAINS ON TRACK TO ENGAGE WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) MID-YEAR TO FORMALIZE THE BB-301 PIVOTAL STUDY DESIGN BENITEC IS WELL-CAPITALIZED TO ADVANCE BB-301 THROUGH COMPLETION OF THE BB-301 PIVOTAL STUDY WITH CASH AS OF MARCH 31, 2026, OF APPROXIMATELY $184.8 MILLION. HAYWARD, CALIF.

BENITEC BIOPHARMA RELEASES THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

-INTERIM CLINICAL RESULTS FOR THE BB-301 PHASE 1B/2A STUDY INCLUDE 12-MONTH POST-TREATMENT FOLLOW-UP RESULTS FOR THE FIRST FOUR COHORT 1 COMPLETERS, 24-MONTH POST-TREATMENT FOLLOW-UP RESULTS FOR THE FIRST COHORT 1 PATIENT, AND INTERIM CLINICAL RESULTS FOR THE FIRST COHORT 2 PATIENT -BB-301 IS THE ONLY CLINICAL-STAGE THERAPEUTIC AGENT IN DEVELOPMENT FOR THE TREATMENT OF DYSPHAGIA IN PATIENTS DIAGNOSED WITH OPMD HAYWARD, CALIF., APRIL 28, 2026 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE ("DDRNAI") PLATFORM, TODAY ANNOUNCED THE ACCEPTANCE OF THE INTERIM CLINICAL RESULTS FROM THE ONGOING BB-301 PHASE 1B/2A FIRST-IN-HUMAN STUDY FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) WITH MODERATE DYSPHAGIA FOR ORAL PRESENTATION AT THE 2026 AMERICAN SOCIETY OF GENE AND CELL THERAPY ANNUAL MEETING (ASGCT).

BENITEC BIOPHARMA ANNOUNCES ORAL PRESENTATION OF INTERIM PHASE 1B/2A CLINICAL STUDY RESULTS FOR HIGH DOSE BB-301 AND CONTINUED DURABLE IMPROVEMENTS FOR LOW DOSE BB-301 AT THE 2026 AMERICAN SOCIETY OF GENE AND CELL THERAPY ANNUAL MEETING

HAYWARD, CALIF., MARCH 10, 2026 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE ("DDRNAI") PLATFORM, IS HOSTING AN INDUSTRY FORUM BREAKFAST AND PRESENTATION ON TUESDAY, MARCH 10, AT THE 2026 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL AND SCIENTIFIC CONFERENCE. THE PRESENTATION WILL HIGHLIGHT THE KEY CLINICAL RESULTS OBSERVED TO DATE FOR OPMD PATIENTS ENROLLED INTO THE BB-301 PHASE 1B/2A CLINICAL TREATMENT STUDY (NCT06185673) AND THE POTENTIAL FOR BB-301 TO TRANSFORM THE TREATMENT LANDSCAPE FOR PATIENTS WITH OPMD.

BENITEC BIOPHARMA TO HOST INDUSTRY FORUM BREAKFAST EVENT AT THE 2026MUSCULAR DYSTROPHY ASSOCIATION CLINICAL AND SCIENTIFIC CONFERENCE ON MARCH 10, 2026, HIGHLIGHTING CONTINUED PROGRESS FOR BB-301, THE ONLY CLINICAL-STAGE THERAPEUTIC IN DEVELOPMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)

 PATIENT 1 OF COHORT 1 HAS NOW COMPLETED THE 24-MONTH FOLLOW-UP TIMEPOINT, AND AT MONTH-24 POST-TREATMENT PATIENT 1 CONTINUED TO DEMONSTRATE THE POWERFUL DISEASE-MODIFYING EFFECTS OF BB-301, WITH DEEPENING IMPROVEMENTS IN POST-SWALLOW RESIDUE AND TOTAL DYSPHAGIC SYMPTOM BURDEN AS COMPARED TO THE 12-MONTH FOLLOW-UP TIMEPOINT

BENITEC BIOPHARMA PROVIDES POSITIVE LONG-TERM CLINICAL STUDY RESULTS FOR BB-301 PHASE 1B/2A CLINICAL TRIAL DEMONSTRATING ROBUST EFFICACY AND CONTINUED DURABILITY OF RESPONSE

 FAST TRACK DESIGNATION WAS GRANTED FOR BB-301 FOLLOWING U.S. FOOD AND DRUG ADMINISTRATION (FDA) REVIEW OF POSITIVE INTERIM CLINICAL STUDY RESULTS AND PROPRIETARY RESPONDER ANALYSIS PLANNED FOR USE IN PIVOTAL STUDY FOR BB-301

BENITEC BIOPHARMA RELEASES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

HAYWARD, CALIF., NOV. 06, 2025 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR THE COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY DNA- DIRECTED RNA INTERFERENCE (DDRNAI) SILENCE AND REPLACE PLATFORM, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5,930,000 SHARES OF ITS COMMON STOCK AND A CONCURRENT REGISTERED DIRECT OFFERING OF 1,481,481 SHARES OF ITS COMMON STOCK WITH LONG-TERM INVESTOR SUVRETTA CAPITAL.

BENITEC BIOPHARMA INC. ANNOUNCES PRICING OF $100 MILLION COMMON STOCK OFFERING

HAYWARD, CALIF., NOV. 05, 2025 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR THE COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY DNA- DIRECTED RNA INTERFERENCE (DDRNAI) SILENCE AND REPLACE PLATFORM, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS TO PURCHASE COMMON STOCK IN LIEU THEREOF) AND INTENDS TO CONDUCT A CONCURRENT REGISTERED DIRECT OFFERING OF ITS COMMON STOCK WITH LONG-TERM INVESTOR SUVRETTA CAPITAL. IN ADDITION, THE COMPANY INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO A NUMBER OF ADDITIONAL SHARES OF ITS COMMON STOCK EQUAL TO 15% OF THE TOTAL NUMBER OF SHARES OF COMMON STOCK (AND PRE-FUNDED WARRANTS TO PURCHASE COMMON STOCK IN LIEU THEREOF) SOLD IN THE UNDERWRITTEN OFFERING, ON THE SAME TERMS AND CONDITIONS. THE OFFERINGS ARE EXPECTED TO CLOSE ON NOVEMBER 7, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. THE OFFERINGS ARE SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

BENITEC BIOPHARMA INC. ANNOUNCES PROPOSED PUBLIC OFFERING

HAYWARD, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE (DDRNAI) PLATFORM, TODAY PROVIDES POSITIVE INTERIM CLINICAL RESULTS FOR THE BB-301 PHASE 1B/2A CLINICAL TRIAL. FOLLOWING ADMINISTRATION OF BB-301, COHORT 1 PATIENTS DEMONSTRATED SIGNIFICANT AND SUSTAINED IMPROVEMENTS ACROSS MULTIPLE CLINICAL MEASURES INCLUDING DYSPHAGIC SYMPTOM BURDEN, POST-SWALLOW RESIDUE ACCUMULATION, TIME REQUIRED TO CONSUME FIXED VOLUMES OF LIQUID, AS WELL AS IMPROVED PHARYNGEAL CLOSURE DURING SWALLOWING. ALL SIX PATIENTS ENROLLED INTO COHORT 1 MET THE FORMAL STATISTICAL CRITERIA FOR RESPONSE TO BB-301, REPRESENTING A 100% RESPONSE RATE. FOLLOWING REVIEW OF THESE ENCOURAGING INTERIM DATA, THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION TO BB-301 FOR THE TREATMENT OF OPMD WITH DYSPHAGIA. BB-301 WAS ALSO PREVIOUSLY GRANTED ORPHAN DRUG DESIGNATION FROM BOTH THE FDA AND EUROPEAN MEDICAL ASSOCIATION (EMA).

BENITEC BIOPHARMA PROVIDES POSITIVE INTERIM CLINICAL STUDY RESULTS FOR BB-301 PHASE 1B/2A CLINICAL TRIAL AND RECEIVES FDA FAST TRACK DESIGNATION FOR BB-301

INVESTOR WEBCAST TO BE HELD ON MONDAY NOVEMBER 3, 2025 AT 8:00 AM EST INVESTOR WEBCAST TO BE HELD ON MONDAY NOVEMBER 3, 2025 AT 8:00 AM EST

BENITEC BIOPHARMA TO PROVIDE PHASE 1B/2A CLINICAL STUDY UPDATE FOR BB-301 IN OCULOPHARYNGEAL MUSCULAR DYSTROPHY

INTERIM CLINICAL STUDY RESULTS FOR COHORT 1 OF THE BB-301 PHASE 1B/2A TREATMENT STUDY ANTICIPATED IN Q4 2025 ENROLLMENT OF THE FIRST SUBJECT INTO COHORT 2 OF THE BB-301 PHASE 1B/2A TREATMENT STUDY EXPECTED IN Q4 2025 HAYWARD, CALIF., SEPT. 22, 2025 (GLOBE NEWSWIRE) -- BENITEC BIOPHARMA INC. (NASDAQ: BNTC) (BENITEC OR COMPANY), A CLINICAL-STAGE, GENE THERAPY-FOCUSED, BIOTECHNOLOGY COMPANY DEVELOPING NOVEL GENETIC MEDICINES BASED ON ITS PROPRIETARY SILENCE AND REPLACE DNA-DIRECTED RNA INTERFERENCE (DDRNAI) PLATFORM, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FULL YEAR ENDED JUNE 30, 2025.

Benitec Biopharma Inc.

BNTC

Price

Financial Reports

No items found.

Press Releases

Benitec Biopharma Inc.

BNTC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BNTC